A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorption of Fexofenadine, a Probe Substrate of P-glycoprotein (Part 2) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two Times Two-way Crossover Study)

Trial Profile

A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorption of Fexofenadine, a Probe Substrate of P-glycoprotein (Part 2) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two Times Two-way Crossover Study)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2014

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Fexofenadine; Quinidine
  • Indications Allergic rhinitis; Arrhythmias; Deep vein thrombosis; Pulmonary embolism; Skin disorders; Stroke; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 28 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top